MR contrast developer Epix Medical has initiated a phase I clinical trial of its EP-2104R contrast agent, which targets blood clots in the body. The agent binds selectively to fibrin, and is designed to provide a bright MR image to allow the detection of small clots in arteries and veins, according to the Cambridge, MA-based vendor.
The trial will be conducted in the U.S. under a Food and Drug Administration investigational new drug (IND) application, which Epix filed in June. Epix is collaborating with Schering of Berlin, Germany, in the development of EP-2104R.
By AuntMinnie.com staff writers
August 6, 2004
Related Reading
Epix names Uprichard president and COO, July 16, 2004
Epix testing MS-325 for cardiac imaging, July 12, 2004
Epix launches new MS-325 trial, July 8, 2004
Schering submits MS-325 for EU approval, June 7, 2004
Epix raises $96 million, June 4, 2004
Copyright © 2004 AuntMinnie.com
